TY - JOUR
T1 - Early versus Late Pharmacologic Thromboprophylaxis in Traumatic Brain Injury
T2 - A Propensity-Score Matched Cohort Study
AU - Jiang, Wei
AU - Ma, Lianwei
AU - Elashhab, Mohamed Gamal Eldin Abd El Hamid
AU - Wu, Xiang
AU - Bai, Lijun
AU - Wang, Zhuonan
N1 - Publisher Copyright:
© 2026 Thieme Medical Publishers, Inc.. All rights reserved.
PY - 2026
Y1 - 2026
N2 - The optimal timing of pharmacological thromboprophylaxis in traumatic brain injury (TBI) remains uncertain due to competing risks of thrombosis and bleeding. This study evaluated whether early heparin initiation (≤72 hours) reduces vascular occlusive events (VOEs), mortality, and hospital stay without increasing bleeding. We compared early versus late (>72 hours) heparin use via propensity score matching (PSM), subgroup analyses, and multivariable logistic regression. Outcomes included VOEs (deep vein thrombosis, pulmonary embolism, myocardial infarction, and ischemic stroke), bleeding, 30- and 180-day mortality, and length of stay. After PSM, late heparin was associated with higher VOEs (25.16 vs. 12.24%, p < 0.001), 30-day mortality (20 vs. 11.89%, p = 0.03), 180-day mortality (32.26 vs. 19.58%, p = 0.004), and prolonged hospitalization (median: 15.7 vs. 9.7 days, p < 0.001), without increased bleeding risk (16.77 vs. 22.03%, p = 0.24). Subgroup analyses revealed late heparin as an independent risk factor for VOEs in mild TBI (odds ratio: 2.62, 95% confidence interval: 1.54-4.45; p < 0.001) regardless of fracture status, coagulation profile, or hemorrhagic classification, with nonsignificant associations in nonhemorrhagic and moderate-to-severe TBI subgroups. Multivariable analysis identified late heparin, higher comorbidity index, elevated platelet count, and cranial surgery as independent predictors of VOEs, with late heparin also independently associated with increased mortality. These findings suggest early heparin initiation reduces thromboembolic complications, mortality, and hospital stay without markedly increasing bleeding risk, supporting early anticoagulation in selected patients following individualized risk-benefit assessment.
AB - The optimal timing of pharmacological thromboprophylaxis in traumatic brain injury (TBI) remains uncertain due to competing risks of thrombosis and bleeding. This study evaluated whether early heparin initiation (≤72 hours) reduces vascular occlusive events (VOEs), mortality, and hospital stay without increasing bleeding. We compared early versus late (>72 hours) heparin use via propensity score matching (PSM), subgroup analyses, and multivariable logistic regression. Outcomes included VOEs (deep vein thrombosis, pulmonary embolism, myocardial infarction, and ischemic stroke), bleeding, 30- and 180-day mortality, and length of stay. After PSM, late heparin was associated with higher VOEs (25.16 vs. 12.24%, p < 0.001), 30-day mortality (20 vs. 11.89%, p = 0.03), 180-day mortality (32.26 vs. 19.58%, p = 0.004), and prolonged hospitalization (median: 15.7 vs. 9.7 days, p < 0.001), without increased bleeding risk (16.77 vs. 22.03%, p = 0.24). Subgroup analyses revealed late heparin as an independent risk factor for VOEs in mild TBI (odds ratio: 2.62, 95% confidence interval: 1.54-4.45; p < 0.001) regardless of fracture status, coagulation profile, or hemorrhagic classification, with nonsignificant associations in nonhemorrhagic and moderate-to-severe TBI subgroups. Multivariable analysis identified late heparin, higher comorbidity index, elevated platelet count, and cranial surgery as independent predictors of VOEs, with late heparin also independently associated with increased mortality. These findings suggest early heparin initiation reduces thromboembolic complications, mortality, and hospital stay without markedly increasing bleeding risk, supporting early anticoagulation in selected patients following individualized risk-benefit assessment.
KW - bleeding events
KW - heparin
KW - mortality
KW - thrombosis
KW - traumatic brain injury
KW - vascular occlusive events
UR - https://www.scopus.com/pages/publications/105047705855
U2 - 10.1055/a-2927-6855
DO - 10.1055/a-2927-6855
M3 - 文章
C2 - 42546743
AN - SCOPUS:105047705855
SN - 0094-6176
JO - Seminars in Thrombosis and Hemostasis
JF - Seminars in Thrombosis and Hemostasis
ER -